Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2003 1
2006 3
2007 4
2008 5
2009 3
2010 7
2011 10
2012 2
2013 8
2014 4
2015 8
2016 6
2017 7
2018 8
2019 7
2020 12
2021 16
2022 10
2023 18
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.
Prosz A, Sahgal P, Huffman BM, Sztupinszki Z, Morris CX, Chen D, Börcsök J, Diossy M, Tisza V, Spisak S, Likasitwatanakul P, Rusz O, Csabai I, Cecchini M, Baca Y, Elliott A, Enzinger P, Singh H, Ubellaker J, Lazaro JB, Cleary JM, Szallasi Z, Sethi NS. Prosz A, et al. Among authors: elliott a. NPJ Precis Oncol. 2024 May 6;8(1):98. doi: 10.1038/s41698-024-00587-w. NPJ Precis Oncol. 2024. PMID: 38710943 No abstract available.
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target across Human Malignancies.
Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, McKay RR, Garje R, Bastos BR, Hoon DS, Orme JJ, Sartor O, Vanderwalde A, Nabhan C, Sledge GW, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Miller CD, et al. Among authors: elliott a. Cancer Res Commun. 2024 May 6. doi: 10.1158/2767-9764.CRC-23-0546. Online ahead of print. Cancer Res Commun. 2024. PMID: 38709075
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.
Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, Graff SL, Antonarakis ES, Goel S, Sledge G, Lopes G. Kareff SA, et al. Among authors: elliott a. Cancers (Basel). 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. Cancers (Basel). 2024. PMID: 38672653 Free PMC article.
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Barata P, Gulati S, Elliott A, Hammers HJ, Burgess EF, Gartrell BA, Darabi S, Bilen MA, Basu A, Geynisman DM, Dawson NA, Zibelman MR, Zhang T, Wei S, Ryan CJ, Heath EI, Poorman KA, Nabhan C, McKay RR. Barata P, et al. Among authors: elliott a. J Clin Invest. 2024 Apr 23:e178915. doi: 10.1172/JCI178915. Online ahead of print. J Clin Invest. 2024. PMID: 38652565 Free article.
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.
Prosz A, Sahgal P, Huffman BM, Sztupinszki Z, Morris CX, Chen D, Börcsök J, Diossy M, Tisza V, Spisak S, Likasitwatanakul P, Rusz O, Csabai I, Cecchini M, Baca Y, Elliott A, Enzinger P, Singh H, Ubellaker J, Lazaro JB, Cleary JM, Szallasi Z, Sethi NS. Prosz A, et al. Among authors: elliott a. NPJ Precis Oncol. 2024 Apr 8;8(1):87. doi: 10.1038/s41698-024-00561-6. NPJ Precis Oncol. 2024. PMID: 38589664 Free PMC article.
Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, Locquet MA, Gottlieb FH, Chen MF, Lee E, Haradon D, Smokovich A, Voligny E, Nguyen T, Goel VK, Zimmerman Z, Atwal S, Wang X, Bahcall M, Heist RS, Iqbal S, Gandhi N, Elliott A, Vanderwalde AM, Ma PC, Halmos B, Liu SV, Che J, Schrock AB, Drilon A, Janne PA, Awad MM. Pecci F, et al. Among authors: elliott a. Cancer Discov. 2024 Apr 3. doi: 10.1158/2159-8290.CD-23-1217. Online ahead of print. Cancer Discov. 2024. PMID: 38564707
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Among authors: elliott a. Nat Cancer. 2024 Mar 25. doi: 10.1038/s43018-024-00752-x. Online ahead of print. Nat Cancer. 2024. PMID: 38528112
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES. Zorko NA, et al. Among authors: elliott a. Prostate Cancer Prostatic Dis. 2024 Feb 28. doi: 10.1038/s41391-024-00797-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38418892
134 results